Rationale: Allogeneic cardiac stem cells (AlloCSC-01) have shown protective,
immunoregulatory, and regenerative properties with a robust safety profile in large animal …

Clinical Track Page 1 579 In May 2018, the average time from submission to first decision for all
original research papers submitted to Circulation Research was 13.37 days. From the …

抄録< jats: sec>< jats: title>< jats: underline> Rationale:</jats: underline></jats: title>< jats:
p> Allogeneic cardiac stem cells (AlloCSC-01) have shown protective, immunoregulatory …

Objective To investigate the safety and feasibility of early administration of AlloCSC-01 in
patients with ST-segment-elevation myocardial infarction. Methods and results CAREMI …

Rationale Allogeneic cardiac stem cells (AlloCSC-01) have shown protective,
immunoregulatory, and regenerative properties with a robust safety profile in large animal …

Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in
Patients With ST-Segment Elevation Myoca Page 1 579 In May 2018, the average time from …